About the ABPI

The ABPI represents innovative resea​rch-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.

Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. We represent companies who supply more than 80 per cent of all branded medicines used by the NHS and who are researching and developing the majority of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome disease.

Globally our industry is researching and developing more than 7,000 new medicines.

The ABPI is recognised by government as the industry body negotiating on behalf of the branded pharmaceutical industry for statutory consultation requirements including the pricing scheme for medicines in the UK.​​​​​​​

Notes to Editor​

* International Committee of Medical Journal Editors. Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals—updated December 2015. Available at: http://www.icmje.org/recommendations/ (Last accessed 23 October 2017)

** World Health Organization. WHO Statement on Public Disclosure of Clinical Trial Results. April 2015. Available at: http://www.who.int/ictrp/results/reporting/en/ (Last accessed 23 October 2017)

All ABPI reports on clinical trial transparency are available for download:

  • Clinical trial transparency of recently approved medicines (2017) can be downloaded here.
  • Clinical trial transparency of recently approved medicines (2016) can be downloaded here.
  • Clinical trial transparency update (2015) can be downloaded here.
  • Clinical trial transparency (2013) can be downloaded here.

Media enquiries


+44 (0) 20 7747 7147​​